WO1998000169A1 - Hydrophobic preparations containing medium chain monoglycerides - Google Patents
Hydrophobic preparations containing medium chain monoglycerides Download PDFInfo
- Publication number
- WO1998000169A1 WO1998000169A1 PCT/GB1997/001775 GB9701775W WO9800169A1 WO 1998000169 A1 WO1998000169 A1 WO 1998000169A1 GB 9701775 W GB9701775 W GB 9701775W WO 9800169 A1 WO9800169 A1 WO 9800169A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- hydrophobic preparation
- hydrophobic
- hydrophilic
- oil phase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU33526/97A AU709013B2 (en) | 1996-07-02 | 1997-07-02 | Hydrophobic preparations containing medium chain monoglycerides |
NZ333115A NZ333115A (en) | 1996-07-02 | 1997-07-02 | Preparation of hydrophillic macromolecules in hydrophobic solvents such as medium chain monoglycerides and diglcerides |
JP10503931A JP2000515130A (en) | 1996-07-02 | 1997-07-02 | Hydrophobic preparations containing medium-chain monoglycerides |
BR9710179A BR9710179A (en) | 1996-07-02 | 1997-07-02 | Hydrophobic preparation preparation in pharmaceutical emulation and use of a hydrophobic preparation |
EP97929411A EP0910411A1 (en) | 1996-07-02 | 1997-07-02 | Hydrophobic preparations containing medium chain monoglycerides |
US09/218,289 US6258377B1 (en) | 1996-07-02 | 1998-12-22 | Hydrophobic preparations containing medium chain monoglycerides |
NO986211A NO986211L (en) | 1996-07-02 | 1998-12-30 | Hydrophobic preparations containing medium chain monoglycerides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9613858.1 | 1996-07-02 | ||
GBGB9613858.1A GB9613858D0 (en) | 1996-07-02 | 1996-07-02 | Hydrophobic preparations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/218,289 Continuation US6258377B1 (en) | 1996-07-02 | 1998-12-22 | Hydrophobic preparations containing medium chain monoglycerides |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998000169A1 true WO1998000169A1 (en) | 1998-01-08 |
Family
ID=10796214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1997/001775 WO1998000169A1 (en) | 1996-07-02 | 1997-07-02 | Hydrophobic preparations containing medium chain monoglycerides |
Country Status (13)
Country | Link |
---|---|
US (1) | US6258377B1 (en) |
EP (1) | EP0910411A1 (en) |
JP (1) | JP2000515130A (en) |
KR (1) | KR20000022353A (en) |
AU (1) | AU709013B2 (en) |
BR (1) | BR9710179A (en) |
CA (1) | CA2259233A1 (en) |
GB (1) | GB9613858D0 (en) |
ID (1) | ID18568A (en) |
NO (1) | NO986211L (en) |
NZ (1) | NZ333115A (en) |
WO (1) | WO1998000169A1 (en) |
ZA (1) | ZA975856B (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000033866A1 (en) * | 1998-12-04 | 2000-06-15 | Provalis Uk Limited | Pharmaceutical compositions containing insulin |
JP2000191684A (en) * | 1998-11-30 | 2000-07-11 | Mcneil Ppc Inc | Production of dispersable sterol and stanol composition |
KR100508695B1 (en) * | 2001-02-13 | 2005-08-17 | 한국과학기술연구원 | Formulation for oral delivery of insulin and preparation method thereof |
US7153930B1 (en) | 1999-07-30 | 2006-12-26 | James Duncan Morrison | Peptide transport |
US20080119443A1 (en) * | 2006-07-03 | 2008-05-22 | Academia Sinica | Certain lithocholic acid analogues that inhibit sialyltransferase |
US8029823B2 (en) | 1999-06-14 | 2011-10-04 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
WO2012152709A1 (en) * | 2011-05-06 | 2012-11-15 | Vaxcine Ltd | Hydrophobic preparations |
WO2012152707A1 (en) * | 2011-05-06 | 2012-11-15 | Vaxcine Ltd | Microemulsions |
US8314058B2 (en) | 2003-04-15 | 2012-11-20 | Axcess Limited | Uptake of macromolecules |
US8377897B2 (en) | 1998-05-21 | 2013-02-19 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
US8691785B2 (en) | 1997-07-01 | 2014-04-08 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
US8802087B2 (en) | 2004-03-22 | 2014-08-12 | Abbott Products Gmbh | Pharmaceutical compositions of lipase-containing products, in particular of pancreation |
US8895064B2 (en) | 1999-06-14 | 2014-11-25 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
US10004704B2 (en) | 2010-10-29 | 2018-06-26 | Infirst Healthcare Limited | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
US10143671B2 (en) | 2010-10-29 | 2018-12-04 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US10154964B2 (en) | 2011-09-07 | 2018-12-18 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US10155042B2 (en) | 2010-10-29 | 2018-12-18 | Infirst Healthcare Limited | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US10213381B2 (en) | 2010-10-29 | 2019-02-26 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US10363232B2 (en) | 2010-10-29 | 2019-07-30 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US10704037B2 (en) | 2005-07-29 | 2020-07-07 | Abbott Products Gmbh | Processes for the manufacture and use of pancreatin |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7169889B1 (en) * | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
CN1255095C (en) * | 1999-10-08 | 2006-05-10 | 科蒂股份有限公司 | Cosmetic preparation of active substances with synergistically increased radical protection factor |
US20030054015A1 (en) * | 2000-12-25 | 2003-03-20 | Shinichiro Haze | Sympathetic-activating perfume composition |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
CN1160122C (en) | 2001-04-20 | 2004-08-04 | 清华大学 | Method of preparing oil-phase oral insulin preparation |
WO2002097038A2 (en) * | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Chemokine beta-1 fusion proteins |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7030082B2 (en) * | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
EP2277889B1 (en) | 2001-12-21 | 2014-07-09 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
GB0308732D0 (en) * | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
CA2910494C (en) | 2004-07-19 | 2018-10-23 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
DE602007009377D1 (en) | 2006-05-30 | 2010-11-04 | Intarcia Therapeutics Inc | SECONDARY FLOW MODULATOR WITH AN INTERNAL CHANNEL FOR AN OSMOTIC OUTPUT SYSTEM |
KR101200728B1 (en) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | Osmotic delivery system and piston assemblies |
AU2008244523B2 (en) | 2007-04-23 | 2012-02-16 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
MX2010003979A (en) | 2007-10-16 | 2010-06-02 | Biocon Ltd | An orally administerable solid pharmaceutical composition and a process thereof. |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
CN102112110A (en) * | 2008-06-06 | 2011-06-29 | 米尔纳医疗股份有限公司 | Novel compositions for the in vivo delivery of RNAi agents |
WO2010113177A2 (en) | 2009-03-31 | 2010-10-07 | Reliance Life Sciences Pvt. Ltd. | Oral insulin delivery systems for controlling diabetes |
SI2462246T1 (en) | 2009-09-28 | 2018-01-31 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
EP2380920A1 (en) | 2010-04-22 | 2011-10-26 | QGel SA | Hydrogel precursor formulation and production process thereof |
EP2594281B1 (en) | 2010-07-14 | 2019-08-28 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | Insulin-lipid complex, preparation method therefor, and preparation thereof |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
JP6243331B2 (en) | 2012-05-31 | 2017-12-06 | テルモ株式会社 | PH-SENSITIVE CARRIER AND METHOD FOR PRODUCING SAME, PH-SENSITIVE MEDICINE CONTAINING THE CARRIER, pH-SENSITIVE PHARMACEUTICAL COMPOSITION AND CULTURE METHOD USING THE SAME |
RU2677346C2 (en) * | 2013-01-14 | 2019-01-16 | ИнФерст Хэлткэр Лимитед | Compositions and methods for treating severe pain |
EP2925367B1 (en) * | 2013-01-14 | 2019-08-14 | InFirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
CA2898017A1 (en) * | 2013-02-04 | 2014-08-07 | Infirst Healthcare Limited | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
KR20240042548A (en) | 2015-06-03 | 2024-04-02 | 인타르시아 세라퓨틱스 인코포레이티드 | Implant placement and removal systems |
MA53353A (en) | 2016-05-16 | 2021-06-09 | Intarcia Therapeutics Inc | GLUCAGON RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS FOR THEIR USE |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0260796A1 (en) * | 1986-09-19 | 1988-03-23 | Yamanouchi Pharmaceutical Co. Ltd. | Compositions of neocarzinostatin derivative for oral administration |
WO1993002664A1 (en) * | 1991-07-26 | 1993-02-18 | Smithkline Beecham Corporation | W/o microemulsions |
WO1994008605A1 (en) * | 1992-10-16 | 1994-04-28 | Smithkline Beecham Corporation | Therapeutic microemulsions |
WO1994008603A1 (en) * | 1992-10-16 | 1994-04-28 | Smithkline Beecham Corporation | Compositions |
WO1994012154A1 (en) * | 1992-11-23 | 1994-06-09 | Cortecs Limited | Lipid containing formulation and method for its preparation |
WO1994019003A1 (en) * | 1993-02-17 | 1994-09-01 | Smithkline Beecham Corporation | Microemulsions comprising therapeutic peptides |
WO1995013795A1 (en) * | 1993-11-16 | 1995-05-26 | Cortecs Limited | Hydrophobic preparations |
WO1996017593A1 (en) * | 1994-12-09 | 1996-06-13 | Cortecs Limited | Solubilisation aids for hydrophilic macromolecules |
WO1996017594A1 (en) * | 1994-12-09 | 1996-06-13 | Cortecs Limited | Sequestration agents |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53107408A (en) * | 1977-02-28 | 1978-09-19 | Yamanouchi Pharmaceut Co Ltd | Micellar preparation for rectal infusion |
ATE2688T1 (en) | 1979-06-11 | 1986-03-15 | Gebrueder Sulzer Aktiengesellschaft | LOOKING THREAD FEED DEVICE FOR A LOOPPING MACHINE. |
GB9422990D0 (en) | 1994-11-15 | 1995-01-04 | Cortecs Ltd | Immunogenic compositions |
GB9605709D0 (en) | 1996-03-19 | 1996-05-22 | Cortecs Ltd | Method |
-
1996
- 1996-07-02 GB GBGB9613858.1A patent/GB9613858D0/en active Pending
-
1997
- 1997-07-01 ZA ZA975856A patent/ZA975856B/en unknown
- 1997-07-02 NZ NZ333115A patent/NZ333115A/en unknown
- 1997-07-02 BR BR9710179A patent/BR9710179A/en not_active Application Discontinuation
- 1997-07-02 ID IDP972303A patent/ID18568A/en unknown
- 1997-07-02 WO PCT/GB1997/001775 patent/WO1998000169A1/en not_active Application Discontinuation
- 1997-07-02 AU AU33526/97A patent/AU709013B2/en not_active Ceased
- 1997-07-02 CA CA002259233A patent/CA2259233A1/en not_active Abandoned
- 1997-07-02 JP JP10503931A patent/JP2000515130A/en active Pending
- 1997-07-02 KR KR1019980710781A patent/KR20000022353A/en not_active Application Discontinuation
- 1997-07-02 EP EP97929411A patent/EP0910411A1/en not_active Withdrawn
-
1998
- 1998-12-22 US US09/218,289 patent/US6258377B1/en not_active Expired - Fee Related
- 1998-12-30 NO NO986211A patent/NO986211L/en not_active Application Discontinuation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0260796A1 (en) * | 1986-09-19 | 1988-03-23 | Yamanouchi Pharmaceutical Co. Ltd. | Compositions of neocarzinostatin derivative for oral administration |
WO1993002664A1 (en) * | 1991-07-26 | 1993-02-18 | Smithkline Beecham Corporation | W/o microemulsions |
WO1994008605A1 (en) * | 1992-10-16 | 1994-04-28 | Smithkline Beecham Corporation | Therapeutic microemulsions |
WO1994008603A1 (en) * | 1992-10-16 | 1994-04-28 | Smithkline Beecham Corporation | Compositions |
WO1994012154A1 (en) * | 1992-11-23 | 1994-06-09 | Cortecs Limited | Lipid containing formulation and method for its preparation |
WO1994019003A1 (en) * | 1993-02-17 | 1994-09-01 | Smithkline Beecham Corporation | Microemulsions comprising therapeutic peptides |
WO1995013795A1 (en) * | 1993-11-16 | 1995-05-26 | Cortecs Limited | Hydrophobic preparations |
WO1996017593A1 (en) * | 1994-12-09 | 1996-06-13 | Cortecs Limited | Solubilisation aids for hydrophilic macromolecules |
WO1996017594A1 (en) * | 1994-12-09 | 1996-06-13 | Cortecs Limited | Sequestration agents |
Cited By (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691785B2 (en) | 1997-07-01 | 2014-04-08 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
US8377897B2 (en) | 1998-05-21 | 2013-02-19 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
JP2000191684A (en) * | 1998-11-30 | 2000-07-11 | Mcneil Ppc Inc | Production of dispersable sterol and stanol composition |
WO2000033866A1 (en) * | 1998-12-04 | 2000-06-15 | Provalis Uk Limited | Pharmaceutical compositions containing insulin |
US9592203B2 (en) | 1999-06-14 | 2017-03-14 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US9532954B2 (en) | 1999-06-14 | 2017-01-03 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical compositions |
US8293273B2 (en) | 1999-06-14 | 2012-10-23 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
USRE43799E1 (en) | 1999-06-14 | 2012-11-13 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US10105374B2 (en) | 1999-06-14 | 2018-10-23 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical compositions |
US10064878B2 (en) | 1999-06-14 | 2018-09-04 | Cosmo Technologies Ltd. | Controlled release and taste masking oral pharmaceutical compositions |
US10052286B2 (en) | 1999-06-14 | 2018-08-21 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US9737489B2 (en) | 1999-06-14 | 2017-08-22 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US10143698B2 (en) | 1999-06-14 | 2018-12-04 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical compositions |
US8784888B2 (en) | 1999-06-14 | 2014-07-22 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US8029823B2 (en) | 1999-06-14 | 2011-10-04 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US8895064B2 (en) | 1999-06-14 | 2014-11-25 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US9320716B2 (en) | 1999-06-14 | 2016-04-26 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical compositions |
US9192581B2 (en) | 1999-06-14 | 2015-11-24 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US7153930B1 (en) | 1999-07-30 | 2006-12-26 | James Duncan Morrison | Peptide transport |
KR100508695B1 (en) * | 2001-02-13 | 2005-08-17 | 한국과학기술연구원 | Formulation for oral delivery of insulin and preparation method thereof |
US8314058B2 (en) | 2003-04-15 | 2012-11-20 | Axcess Limited | Uptake of macromolecules |
US8802087B2 (en) | 2004-03-22 | 2014-08-12 | Abbott Products Gmbh | Pharmaceutical compositions of lipase-containing products, in particular of pancreation |
US10704037B2 (en) | 2005-07-29 | 2020-07-07 | Abbott Products Gmbh | Processes for the manufacture and use of pancreatin |
US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
US8940719B2 (en) * | 2006-07-03 | 2015-01-27 | Academia Sinica | Lithocholic acid analogues that inhibit sialyltransferase |
US20080119443A1 (en) * | 2006-07-03 | 2008-05-22 | Academia Sinica | Certain lithocholic acid analogues that inhibit sialyltransferase |
US10154975B2 (en) | 2010-10-29 | 2018-12-18 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US11154500B2 (en) | 2010-10-29 | 2021-10-26 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US11918654B2 (en) | 2010-10-29 | 2024-03-05 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US10004704B2 (en) | 2010-10-29 | 2018-06-26 | Infirst Healthcare Limited | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US10155042B2 (en) | 2010-10-29 | 2018-12-18 | Infirst Healthcare Limited | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US11844773B2 (en) | 2010-10-29 | 2023-12-19 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US10188619B2 (en) | 2010-10-29 | 2019-01-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US10213381B2 (en) | 2010-10-29 | 2019-02-26 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US10231943B2 (en) | 2010-10-29 | 2019-03-19 | Infirst Healthcare Limited | Compositions and methods for treating cardiovascular diseases |
US11826428B2 (en) | 2010-10-29 | 2023-11-28 | Infirst Healthcare Limited | Solid solution compositions comprising cannabidiols |
US10363232B2 (en) | 2010-10-29 | 2019-07-30 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US10426748B2 (en) | 2010-10-29 | 2019-10-01 | Infirst Healthcare Limited | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US10588878B2 (en) | 2010-10-29 | 2020-03-17 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US10596132B2 (en) | 2010-10-29 | 2020-03-24 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US10653778B2 (en) | 2010-10-29 | 2020-05-19 | Infirst Healthcare Limited | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US11660276B2 (en) | 2010-10-29 | 2023-05-30 | Infirst Healthcare Limited | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US10835490B2 (en) | 2010-10-29 | 2020-11-17 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US10849869B2 (en) | 2010-10-29 | 2020-12-01 | Infirst Healthcare Limited | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US10857114B2 (en) | 2010-10-29 | 2020-12-08 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US11000493B2 (en) | 2010-10-29 | 2021-05-11 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US11065218B2 (en) | 2010-10-29 | 2021-07-20 | Infirst Healthcare Limited | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US11103472B2 (en) | 2010-10-29 | 2021-08-31 | Infirst Healthcare Limited | Oral suspensions comprising a non-steroidal anti-inflammatory drug (NSAID) |
US10143671B2 (en) | 2010-10-29 | 2018-12-04 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
WO2012152709A1 (en) * | 2011-05-06 | 2012-11-15 | Vaxcine Ltd | Hydrophobic preparations |
WO2012152707A1 (en) * | 2011-05-06 | 2012-11-15 | Vaxcine Ltd | Microemulsions |
US10660858B2 (en) | 2011-09-07 | 2020-05-26 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US10307375B2 (en) | 2011-09-07 | 2019-06-04 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US10172799B1 (en) | 2011-09-07 | 2019-01-08 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US10154964B2 (en) | 2011-09-07 | 2018-12-18 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
Also Published As
Publication number | Publication date |
---|---|
BR9710179A (en) | 1999-08-10 |
EP0910411A1 (en) | 1999-04-28 |
NO986211L (en) | 1999-03-02 |
NZ333115A (en) | 2000-06-23 |
GB9613858D0 (en) | 1996-09-04 |
ZA975856B (en) | 1999-01-04 |
ID18568A (en) | 1998-04-23 |
AU3352697A (en) | 1998-01-21 |
KR20000022353A (en) | 2000-04-25 |
CA2259233A1 (en) | 1998-01-08 |
JP2000515130A (en) | 2000-11-14 |
US6258377B1 (en) | 2001-07-10 |
NO986211D0 (en) | 1998-12-30 |
AU709013B2 (en) | 1999-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU709013B2 (en) | Hydrophobic preparations containing medium chain monoglycerides | |
EP0587659B1 (en) | Pharmaceutical carrier | |
Willimann et al. | Lecithin organogel as matrix for transdermal transport of drugs | |
Treffel et al. | Effect of occlusion on in vitro percutaneous absorption of two compounds with different physicochemical properties | |
US5120710A (en) | Oral lipid medicinal composition | |
US5688761A (en) | Convertible microemulsion formulations | |
Kararli et al. | Oral delivery of a renin inhibitor compound using emulsion formulations | |
Venkataram et al. | Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid | |
WO1998037869A1 (en) | Fat emulsion for oral administration | |
KR20020066776A (en) | Formulation for oral delivery of insulin and preparation method thereof | |
CA2612128C (en) | Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients | |
WO1997030695A1 (en) | Drug delivery compositions suitable for intravenous injection | |
US20040147578A1 (en) | Use of lipoaminoacids as absorption promoters in a pharmaceutical composition | |
PT100400B (en) | MICROEMULATIONS FORMULATIONS CONVERTIVEIS | |
US20020115592A1 (en) | Pharmaceutical compositions containing insulin | |
JP2740465B2 (en) | A novel pharmacological dosage form for transdermal administration | |
Mikov et al. | The influence of 3α, 7α-dihydroxy-12-keto-5β-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes | |
EP0746331B1 (en) | Convertible microemulsion formulations | |
Luner et al. | The effects of bile salts and lipids on the physicochemical behavior of gemfibrozil | |
AU764413B2 (en) | A pharmaceutical composition comprising cyclosporin in a lipid carrier | |
WO1996010991A1 (en) | Pharmaceutical composition containing derivatives of sex hormones | |
MXPA99000275A (en) | Hydrophobic preparations containing monoglycerides of average chain | |
CN102905693A (en) | Water-soluble pharmaceutical composition comprising at least one therapeutically active substance having hydrophobic properties and at least one compound selected from among sialoglycosphingolipids, glycosphingolipids or a mixture of sialoglycosphingolipids and glycosphingolipids | |
WO1999043299A2 (en) | Oral formulation for hydrophilic drugs | |
Imai et al. | Mutual effect of egg albumin and fatty acids on bioavailability of dl-α-tocopherol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97196069.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 333115 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09218289 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2259233 Country of ref document: CA Ref document number: 2259233 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980710781 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/000275 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997929411 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997929411 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980710781 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997929411 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019980710781 Country of ref document: KR |